Halofantrine Dosage
Applies to the following strengths: 250 mg
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Malaria
Mild to moderate Plasmodium falciparum and Plasmodium vivax malaria:
Nonimmune patients: 500 mg orally every 6 hours for 3 doses; repeat course in 7 days.
Semi-immune patients: 500 mg orally every 6 hours for 3 doses. Consideration may be given to omitting the second course.
Usual Pediatric Dose for Malaria
Mild to moderate Plasmodium falciparum and Plasmodium vivax malaria:
<18 years, <40 kg: 8 mg/kg orally every 6 hours for 3 doses. Repeat course in 7 days if patient is nonimmune.
<18 years, >=40 kg:
Nonimmune patients: 500 mg orally every 6 hours for 3 doses; repeat course in 7 days.
Semi-immune patients: 500 mg orally every 6 hours for 3 doses. Consideration may be given to omitting the second course.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Halofantrine prolongs the QTc interval at recommended doses. Ventricular arrhythmias and death (including sudden death) have been reported. This effect is dose-dependent; therefore, recommended doses should not be exceeded.
Halofantrine is contraindicated in patients with a family history of congenital QTc interval prolongation. Its use is not recommended in conditions or other drugs which are known to prolong the QTc interval or in patients with suspected ventricular dysrhythmias, AV conduction disturbances, or unexplained syncopal attacks.
Halofantrine should not be given to patients who have recently taken or are concomitantly taking mefloquine for malaria treatment or prophylaxis, due to the risk of potentially fatal QT interval prolongation.
ECGs should be performed before treatment to ascertain that baseline QTc is within normal limits. Cardiac rhythm should be monitored during therapy and for 8 to 12 hours after completion of each course of therapy.
Patients with severe or life-threatening malaria should be treated with a parenteral antimalarial agents. Its efficacy has not been established in the treatment of cerebral malaria or other types of complicated malaria.
Caution is recommended with concurrent drugs that are significant CYP450 3A4 inhibitors, because its metabolism may be decreased, leading to higher plasma levels and an increased risk of QT interval prolongation.
Dialysis
Data not available
Other Comments
Administer on an empty stomach, at least 1 hour before or 2 hours after food.
To avoid relapse due to exoerythrocytic parasites, patients should be treated with an 8-aminoquinoline antimalarial agent (e.g., primaquine) after halofantrine treatment.
More about halofantrine
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: miscellaneous antimalarials
- Breastfeeding
Patient resources
Related treatment guides
See also:
Plaquenil
Plaquenil is used to treat or prevent malaria and to treat the symptoms of rheumatoid arthritis ...
Vibramycin
Vibramycin is used for acne, actinomycosis, amebiasis, anthrax, anthrax prophylaxis, bacterial ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Cleocin
Cleocin (clindamycin) is used to treat serious bacterial infections. Includes Cleocin side effects ...
Quinine
Quinine systemic is used for malaria, myotonia congenita, nocturnal leg cramps
Atovaquone
Atovaquone systemic is used for babesiosis, malaria, pneumocystis pneumonia, pneumocystis pneumonia ...
Clindamycin
Clindamycin (Cleocin) is used to treat serious infections caused by bacteria. Includes clindamycin ...
Hydroxychloroquine
Hydroxychloroquine is a quinoline drug used to treat or prevent malaria. It's also used to treat ...
Doxycycline
Doxycycline is a tetracycline antibiotic used to treat many different bacterial infections such as ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.